AR049170A1 - Derivados de pirimidina para el tratamiento del crecimiento celular anormal - Google Patents

Derivados de pirimidina para el tratamiento del crecimiento celular anormal

Info

Publication number
AR049170A1
AR049170A1 ARP050101939A ARP050101939A AR049170A1 AR 049170 A1 AR049170 A1 AR 049170A1 AR P050101939 A ARP050101939 A AR P050101939A AR P050101939 A ARP050101939 A AR P050101939A AR 049170 A1 AR049170 A1 AR 049170A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
heterocyclyl
cycloalkyl
hydrogen
Prior art date
Application number
ARP050101939A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR049170A1 publication Critical patent/AR049170A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

La presente se refiere a composiciones farmacéuticas que contienen dichos compuestos. Reivindicacion 1: Un compuesto descrito por la formula (1), o una sal, solvato, hidrato o profármaco suyo farmacéuticamente aceptable, en el que Ar es seleccionado entre un grupo de formula (2), y el anillo B es una formula (3), en el que m es un numero entero entre 0 y 2; Ra representa sustituyentes seleccionados de forma independiente del grupo que consiste en hidrogeno, halogeno, hidroxi, -CF3, -CN, -NR1R2, -OR1, -R1, -CO2R1 y -CONR1R2; Rb representa un sustituyente seleccionado del grupo que consiste en hidrogeno, alquilo-C1-6, cicloalquilo-C3-7, heterociclilo-C2-9, -CO2R1, -CONR1R2; cada Rc representa de forma independiente un sustituyente seleccionado del grupo que consiste en hidrogeno, halogeno, hidroxi, -CF3, -CN, alquilo-C1-6, -NR1R2, -OR1, cicloalquilo-C3-7, heterociclilo-C2-9, -CO2R1 y -CONR1R2 o se pueden considerar dos sustituyentes Rc en conjunto con el átomo(s) al que están unidos para formar un grupo cíclico, cicloalquilo-C3-10 o heterociclilo-C2-9; A es un resto cíclico adecuadamente sustituido seleccionado del grupo que consiste en: a) un grupo heterociclilo-C2-9 incluyendo el átomo de nitrogeno del anillo de la union entre el resto cíclico A y la posicion C-4 del anillo de pirimidina de formula (1); y b) un grupo heterociclilo-C2-7 en el que dos carbonos metilénicos adyacentes de dicho grupo heterociclilo-C2-7 están unidos a un grupo fenilo o heteroarilo-C2-6; en el que A está sustituido opcionalmente por de 1 a 3 sustituyentes seleccionados de forma independiente del grupo que consiste en halogeno, hidroxilo, ciano, -R1, -NR1R2, -NH(CO)R1, -NR2(CO)R1, alquilo-C1-6-NR1R2, alquilo-C1-6- NH(CO)R1, alquilo-C1-6-NR2(CO)R1, -NHSO2R1, -N(R2)(SO2)(R1), alquilo-C1-6-(SO2)(R1), alquilo-C1-6(NHSO2)(R1), alquilo-C1-6(NR2(SO2)(R1), -OR1, alquilo-C1-6-OR1, alquilo-C1-6-OSOR1, -O-SO2R1, -SO2R1, SO2NH2, SO2NHR1 y -SO2NR1R2; y dicho grupo cíclico A está opcionalmente interrumpido por de uno a tres elementos seleccionados del grupo que consiste en -(C=O), -SO2, -S-, -O-, -N-, -NH- y -NR3; R1 y R2 son cada uno sustituyentes seleccionados de forma independiente del grupo que consiste en hidrogeno, alquilo-C1-6, cicloalquilo-C3-7, heterociclilo-C2-9, arilo-C6-10, y heteroarilo-C1-9; en el que dichos sustituyentes de R1 y R2, alquilo-C1-6, cicloalquilo-C3-7, heterociclilo-C2-9, arilo-C6-10, y heteroarilo-C1-9, están sustituidos opcionalmente por de uno a tres restos seleccionados de forma independiente del grupo que consiste en hidrogeno, halogeno, -CF3, -CN, alquilo-C1-6, -NH-alquilo-C1-6, -NH-cicloalquilo-C3-7, -NH-heterociclilo-C2-9, -NH-arilo-C6-10,-NH-heteroarilo-C1- 9, -N-(alquilo-C1-6)2, -N-(cicloalquilo-C3-7)2, -N(heterociclilo-C2-9)2, -N-(arilo-C6-10)2, -N-(heteroarilo-C1-9)2, -O-(alquilo-C1-6, O-cicloalquilo-C3-7, -O-heterociclilo-C2-9, -O-arilo-C6-10, -O-heteroarilo-C1-9, cicloalquilo-C3-7 y heterociclilo- C2-9; o R1 y R2 pueden ser considerados en conjunto con el átomo(s) a los que están unidos para formar un cicloalquilo-C3-10 o un heterociclilo-C2-9, en el que dicho cicloalquilo-C3-10 o heterociclilo-C2-9 está sustituido opcionalmente por de uno a tres elementos seleccionados del grupo que consiste en hidrogeno, halogeno, e hidroxi, y dicho grupo cíclico está interrumpido opcionalmente por de uno a tres elementos seleccionados del grupo que consiste en -(C=O), -SO2, -S-, -O-, -N-, -NH- y - NR3; R3 es un sustituyentes seleccionado del grupo que consiste en hidrogeno, alquilo-C1-6, cicloalquilo-C3-7, heterociclilo-C2-9, arilo-C6-10, heteroarilo-C1-9, -COR1, y -SO2R1; en el que dichos radicales de R3, alquilo-C1-6, cicloalquilo-C3-7, heterociclilo-C2-9, arilo-C6-10, heteroarilo-C1-9, -COR1, y SO2R1 están sustituidos opcionalmente por de uno a tres restos seleccionados de forma independiente del grupo que consiste en hidrogeno, halogeno, hidroxi, -CN, alquilo-C1-6, -NH2, -NHR4, - NR42, -OR4, cicloalquilo-C3-7, heterociclilo-C2-9, -COR5, -CONH2, -CONHR5, y -CONR5R6, en el que R5 y R6 en -CONR5R6 pueden ser considerados en conjunto con los átomos a los que están unidos para formar un heterociclilo-C2-9; R4 y R5 son cada uno un alquilo-C1-6; y R6 es un hidrogeno o un alquilo-C1-6.
ARP050101939A 2004-05-14 2005-05-12 Derivados de pirimidina para el tratamiento del crecimiento celular anormal AR049170A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57121004P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
AR049170A1 true AR049170A1 (es) 2006-07-05

Family

ID=34967615

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101939A AR049170A1 (es) 2004-05-14 2005-05-12 Derivados de pirimidina para el tratamiento del crecimiento celular anormal

Country Status (10)

Country Link
US (1) US7208499B2 (es)
EP (1) EP1756090A1 (es)
JP (1) JP2007537235A (es)
AR (1) AR049170A1 (es)
BR (1) BRPI0511132A (es)
CA (1) CA2566477A1 (es)
HN (1) HN2005000212A (es)
MX (1) MXPA06011658A (es)
TW (1) TW200607801A (es)
WO (1) WO2005111024A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
PT1625121E (pt) * 2002-12-20 2010-03-11 Pfizer Prod Inc Derivados de piridina para o tratamento de crescimento celular anormal
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
CA2632149C (en) * 2005-12-01 2011-11-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2652773A1 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
US8258129B2 (en) * 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
AR063278A1 (es) * 2006-10-12 2009-01-14 Xenon Pharmaceuticals Inc Compuestos de espiro-oxindol, una composicion farmaceutica que los comprende y su uso para el tratamiento de enfermedades o condiciones mediadas por los canales de sodio.
CA2666136A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
CN103951658B (zh) * 2007-04-18 2017-10-13 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
WO2008130637A1 (en) * 2007-04-18 2008-10-30 New York University Hydrazide compounds as thyroid hormone receptor modulators and uses thereof
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
CN101809024A (zh) * 2007-07-16 2010-08-18 铂雅制药公司 吡铂的口服制剂
EP2249644A4 (en) * 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc PICOPLATIN AND AMRUBICIN USEFUL IN THE TREATMENT OF LUNG CANCER
EP2350090B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MY179342A (en) 2009-10-14 2020-11-04 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
JP6000273B2 (ja) 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ，エルエルシー 大環状キナーゼ阻害剤
AU2012216893B2 (en) 2011-02-17 2016-08-11 Cancer Therapeutics Crc Pty Limited FAK inhibitors
WO2012110774A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
US9187453B2 (en) 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20140135497A1 (en) * 2012-11-13 2014-05-15 Boehringer Ingelheim International Gmbh Synthesis of 2,4-dichloro-5-trifluoromethyl-pyrimidine
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
US5500037A (en) * 1988-12-06 1996-03-19 Alhamad; Shaikh G. M. Y. Impact Absorber
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
DE4137291A1 (de) 1991-11-13 1993-05-19 Bayer Ag Verfahren zur kontinuierlichen umsetzung von halogenpyrimidinen mit aminen
AU2954992A (en) 1991-11-13 1993-06-15 Mta Kozponti Kemiai Kutato Intezete Process for preparing n-(arylsulphonyl)-carbamide acid derivates and intermediates useful for carrying out this process
FR2686339B1 (fr) 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0642502B1 (en) 1992-05-22 2000-07-12 E.I. Du Pont De Nemours And Company Fungicidal imidazolinones
PL326083A1 (en) 1995-10-02 1998-08-17 Hoffmann La Roche Novel pyrimidin derivatives as antagonists of 5ht 2c receptor
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US6492520B1 (en) 1996-08-06 2002-12-10 Pfizer Inc Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
BR9712005A (pt) 1996-09-04 1999-08-24 Pfizer Derivados de indazol e seus usos como inibidores de fosfodiesterase (pde) tipo IV e produ-Æo do fator de necrose de tumor (tnf)
ATE345339T1 (de) 1997-02-19 2006-12-15 Berlex Lab N-heterocyclische derivate als nos inhibitoren
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
WO2000018740A1 (en) 1998-09-29 2000-04-06 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
MXPA02007957A (es) 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
YU63602A (sh) * 2000-02-24 2006-01-16 Biogal Gyogyszergyar Rt. Postupak za prečišćavanje fermentacionog bujona
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CN1190197C (zh) 2000-03-13 2005-02-23 惠氏控股公司 氰基喹啉用于制备治疗或抑制结肠息肉药物中的用途
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
JP2004510706A (ja) 2000-07-07 2004-04-08 キャンサー・リサーチ・テクノロジー・リミテッド 治療用アクリドン及びアクリジン化合物
US6887874B2 (en) 2000-08-09 2005-05-03 Astrazeneca Ab Cinnoline compounds
EP1311500A2 (en) 2000-08-09 2003-05-21 AstraZeneca AB Indole, azaindole and indazole derivatives having vegf inhibiting activity
WO2002016348A1 (en) 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
US7115615B2 (en) 2000-08-21 2006-10-03 Astrazeneca Quinazoline derivatives
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
SI2311825T1 (sl) 2000-12-21 2016-02-29 Novartis Ag Pirimidinamini kot angiogenetski modulatorji
RS94703A (en) * 2001-05-29 2007-02-05 Schering Aktiengesellschaft, Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
ES2314106T3 (es) * 2001-10-17 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Derivados de pirimidina, agentes farmaceuticos que contiene dichos compuestos, uso y metodo para su obtencion.
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003217323A1 (en) 2002-02-05 2003-09-02 Wyeth Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PT1625121E (pt) * 2002-12-20 2010-03-11 Pfizer Prod Inc Derivados de piridina para o tratamento de crescimento celular anormal

Also Published As

Publication number Publication date
HN2005000212A (es) 2009-06-01
MXPA06011658A (es) 2006-12-14
CA2566477A1 (en) 2005-11-24
JP2007537235A (ja) 2007-12-20
WO2005111024A1 (en) 2005-11-24
EP1756090A1 (en) 2007-02-28
BRPI0511132A (pt) 2007-11-27
US20050256144A1 (en) 2005-11-17
US7208499B2 (en) 2007-04-24
TW200607801A (en) 2006-03-01

Similar Documents

Publication Publication Date Title
AR049170A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR049424A1 (es) Derivados de pirimidina inhibidores de quinasa y tirosina quinasa no receptora para el tratamiento del crecimiento celular anormal y composiciones farmaceuticas que los contienen como principio activo.
AR049169A1 (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal
AR068106A1 (es) Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
NO20082101L (no) Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer
EA200800478A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR066492A1 (es) Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres.
AR068107A1 (es) Derivados indolicos 2,3 sustituidos y una composicion farmaceutica
AR075090A1 (es) Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AR068108A1 (es) Derivados azaindol 2,3-sustituidos y una composicion farmaceutica
AR047969A1 (es) Pirazolotriazinas como inhibidores de quinasa
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
AR042956A1 (es) Inhibidores de girasa y usos de los mismos
AR074052A1 (es) Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR064429A1 (es) Derivados indolicos con anillo unidos en las posiciones 4,5, composiciones farmaceuticas que los contienen y usos de los mismos en la prevencion y/o tratamiento de infecciones virales.
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR062050A1 (es) Derivados de amina utiles como agentes anti-cancerigenos
AR047682A1 (es) Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina
AR043682A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los contienen y su uso para el tratamiento del crecimiento celular anormal
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
AR068898A1 (es) Compuestos de tienopirimidinas y pirazolopirimidina y su uso como inhibidores de mtor y pi3k
AR056964A1 (es) Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos
NZ711064A (en) Pyridone-substituted pyrazolyl compounds as serine protease inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure